{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-26-000003","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.884537+00:00","generated_at":"2026-05-16T11:40:46.125455+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026","bullets":["2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.","mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.","Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.","Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.","Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000003","json":"https://secwatch.observer/filing/0001682852-26-000003.json","markdown":"https://secwatch.observer/filing/0001682852-26-000003.md","text":"https://secwatch.observer/filing/0001682852-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/0001682852-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/mrna-20260105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:40:46.125455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}